Biotech company Propanc raises $100 million for crypto reserves and cancer therapy development
Jinse Finance reported that Australia-based Propanc Biopharma (NASDAQ: PPCB) announced on Monday that it has secured up to 100 million dollars in financing from Hexstone Capital. Hexstone Capital is a family office active in the fields of bitcoin, ethereum, solana, dogecoin, and other digital assets. This private placement deal, structured through convertible preferred shares, provides Propanc with an initial investment of 1 million dollars and up to an additional 99 million dollars in follow-up financing over the next year. The proceeds will be used to build Propanc's digital asset portfolio and accelerate the development of its leading tumor therapy, PRP, which is currently targeted for its first human trial in 2026. CEO James Nathanielsz described this move as a "transformational phase," though the company did not specify which digital assets it plans to acquire.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analysis: Wall Street Is Not Yet Ready to Short AI in Large Numbers
Overseas capital is aggressively buying US stocks! Net inflows reached $942 billions over the past 12 months, marking a record since 1985.
According to data from the US Department of the Treasury, in the 12 months ending July this year, overseas investors made net purchases of US stocks totaling $942 billion, marking the highest rolling 12-month total since records began in 1985. The net purchases in the second quarter alone reached $426 billion, setting a new single-quarter record. Meanwhile, overseas demand for US Treasuries has noticeably cooled, with purchase volumes falling significantly. As a result, the US is facing higher costs in government debt financing.
RootData: BIO will unlock tokens worth about $1 million in one week
Crypto prices
More
